Results 111 to 120 of about 2,434,011 (201)

Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial. [PDF]

open access: yesJ Immunother Cancer
Hong H   +19 more
europepmc   +1 more source

Tim Birkhead [PDF]

open access: yesCurrent Biology, 2015
openaire   +1 more source

Hsp70s regulate circadian rhythm by interacting with PERIOD. [PDF]

open access: yesCell Commun Signal
Zhao X   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy